206 related articles for article (PubMed ID: 37932277)
41. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
42. Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition.
Sha J; Bai Y; Ngo HX; Okui T; Kanno T
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208465
[TBL] [Abstract][Full Text] [Related]
43. Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro.
Yan C; Zhao L; Zhang X; Chu Z; Zhou T; Zhang Y; Geng S; Guo K
J Biophotonics; 2024 Mar; 17(3):e202300356. PubMed ID: 38041219
[TBL] [Abstract][Full Text] [Related]
44. Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells.
Chen WC; Lai YA; Lin YC; Ma JW; Huang LF; Yang NS; Ho CT; Kuo SC; Way TD
J Agric Food Chem; 2013 Dec; 61(48):11817-24. PubMed ID: 24236784
[TBL] [Abstract][Full Text] [Related]
45. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
46. Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways.
Jamal SME; Alamodi A; Wahl RU; Grada Z; Shareef MA; Hassan SY; Murad F; Hassan SL; Santourlidis S; Gomez CR; Haikel Y; Megahed M; Hassan M
Oncogene; 2020 Aug; 39(32):5468-5478. PubMed ID: 32616888
[TBL] [Abstract][Full Text] [Related]
47. A cross-talk between stromal cell-derived factor-1 and transforming growth factor-beta controls the quiescence/cycling switch of CD34(+) progenitors through FoxO3 and mammalian target of rapamycin.
Chabanon A; Desterke C; Rodenburger E; Clay D; Guerton B; Boutin L; Bennaceur-Griscelli A; Pierre-Louis O; Uzan G; Abecassis L; Bourgeade MF; Lataillade JJ; Le Bousse-Kerdilès MC
Stem Cells; 2008 Dec; 26(12):3150-61. PubMed ID: 18757300
[TBL] [Abstract][Full Text] [Related]
48. PDGF-induced PI3K-mediated signaling enhances the TGF-β-induced osteogenic differentiation of human mesenchymal stem cells in a TGF-β-activated MEK-dependent manner.
Yokota J; Chosa N; Sawada S; Okubo N; Takahashi N; Hasegawa T; Kondo H; Ishisaki A
Int J Mol Med; 2014 Mar; 33(3):534-42. PubMed ID: 24378341
[TBL] [Abstract][Full Text] [Related]
49. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
50. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.
Radić M; Vlašić I; Jazvinšćak Jembrek M; Horvat A; Tadijan A; Sabol M; Dužević M; Herak Bosnar M; Slade N
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077308
[TBL] [Abstract][Full Text] [Related]
51. Transforming growth factor-beta1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects.
Marone M; Scambia G; Bonanno G; Rutella S; de Ritis D; Guidi F; Leone G; Pierelli L
Leukemia; 2002 Jan; 16(1):94-105. PubMed ID: 11840268
[TBL] [Abstract][Full Text] [Related]
52. Transforming growth factor beta1 regulates follistatin mRNA expression during in vitro bovine granulosa cell differentiation.
Fazzini M; Vallejo G; Colman-Lerner A; Trigo R; Campo S; Barañao JL; Saragüeta PE
J Cell Physiol; 2006 Apr; 207(1):40-8. PubMed ID: 16245315
[TBL] [Abstract][Full Text] [Related]
53. TGF-β and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells.
Suwanabol PA; Seedial SM; Zhang F; Shi X; Si Y; Liu B; Kent KC
Am J Physiol Heart Circ Physiol; 2012 Jun; 302(11):H2211-9. PubMed ID: 22447946
[TBL] [Abstract][Full Text] [Related]
54. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
[TBL] [Abstract][Full Text] [Related]
55. A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer.
Chen J; Dai J; Kang Z; Yang T; Zhao Q; Zheng J; Zhang X; Zhang J; Xu J; Sun G; Yang L; Yang T
Exp Cell Res; 2020 Aug; 393(1):112060. PubMed ID: 32407729
[TBL] [Abstract][Full Text] [Related]
56. Stability and multiattractor dynamics of a toggle switch based on a two-stage model of stochastic gene expression.
Strasser M; Theis FJ; Marr C
Biophys J; 2012 Jan; 102(1):19-29. PubMed ID: 22225794
[TBL] [Abstract][Full Text] [Related]
57. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
58. KDM6B Counteracts EZH2-Mediated Suppression of
Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
[TBL] [Abstract][Full Text] [Related]
59. Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
Ferretti LP; Böhi F; Leslie Pedrioli DM; Cheng PF; Ferrari E; Baumgaertner P; Alvarado-Diaz A; Sella F; Cereghetti A; Turko P; Wright RH; De Bock K; Speiser DE; Ferrari R; Levesque MP; Hottiger MO
Cancer Res; 2023 Dec; 83(23):3974-3988. PubMed ID: 37729428
[TBL] [Abstract][Full Text] [Related]
60. Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.
Najem A; Krayem M; Sabbah S; Pesetti M; Journe F; Awada A; Désaubry L; Ghanem GE
Cells; 2023 Jul; 12(14):. PubMed ID: 37508519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
